Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors

NCT02952989 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT02952989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02952989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 23, 2017
Completion date
June 24, 2019
Enrollment
47 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, carcinoma, non-small-cell lung, carcinoma, renal cell, carcinoma, squamous cell of head and neck, colorectal neoplasms, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, urinary bladder neoplasm